VKValeria O. Kaibysheva

Valeria O. Kaibysheva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valeria O. Kaibysheva has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biological Therapy for Complicated Forms of Eosinophilic Esophagitis

    by V. O. Kaybysheva, A. S. Balabanov, A. I. Mokritskiy, E. V. Gorbachev, K. S. Maslyonkina, L. M. Mikhaleva, E. D. Fedorov, S. G. Shapovalianc, В. О. Кайбышева, А. С. Балабанов, et al.

    Aim: to evaluate the efficacy and safety of dupilumab, a biologic therapy, in the treatment of refractory eosinophilic esophagitis complicated by esophageal strictures and food impaction, in patients who have failed prior therapy with proton pump inhibitors and topical glucocorticosteroids. Materials and methods. In a prospective study conducted from July 2024 to February 2026, 19 patients (2 females, 17 males) aged 19 to 70 years with a previously confirmed diagnosis of eosinophilic esophagitis were administered dupilumab at a dose of 300 mg once weekly subcutaneously for 12 weeks. Indications for dupilumab administration included a complicated disease course (esophageal strictures and narrowing, esophageal dissection, recurrent episodes of acute food impaction) in the setting of resistance to prior therapy with topical glucocorticosteroids and/or proton pump inhibitors. Additional criteria for initiating biologic therapy included coexisting T2-associated diseases, such as bronchial asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. All patients underwent assessment of dysphagia severity according to the Dysphagia Symptom Questionnaire (DSQ), calculation of the clinical and morphological disease activity index, esophagogastroduodenoscopy with esophageal biopsy (at least 6 biopsy specimens from the distal and middle/proximal esophagus), and histopathological examination of biopsy specimens both prior to treatment and at 12 weeks of therapy. Results. At 12 weeks of dupilumab therapy, complete resolution of dysphagia was observed in 9 (75 %) of 12 patients with dysphagia at baseline, and clinical remission (absence of any complaints) was achieved in 12 (63.2 %) of 19 patients. The mean DSQ score, reflecting dysphagia severity, decreased from 32.01 to 7.12 (p < 0.05). Endoscopic disease activity, as assessed by the EREхFS score, decreased from 5.0 [4.0; 7.0] to 1.0 [1.0; 3.0] points (p < 0.0001). Although the proportion of patients with strictures did not change significantly, an increase in esophageal diameter at the stricture site was observed (from 13.1 ± 5.8 mm to 16.1 ± 2.0 mm; p < 0.05). Histological remission (< 15 eosinophils per HPF, ×400) was achieved in 18 (94.7 %) of 19 patients. Adverse events included upper extremity joint pain (1 patient, 5.3 %), conjunctival dryness (2 patients, 10.5 %), and peripheral blood eosinophilia with elevated liver enzymes up to 3–4 times the upper limit of normal (1 patient, 5.3 %). Conclusions. Dupilumab therapy over 12 weeks leads to the achievement of clinical (63.2 %) and histological (94.7 %) remission in eosinophilic esophagitis.

  • Fibrostenotic complications of eosinophilic esophagitis

    by A.I. Mokritsky, V.O. Kaybysheva, E.D. Fedorov, S.G. Shapovalianc

    Objective. To present clinical case description of complicated eosinophilic esophagitis, including an analysis of disease course features, diagnostic criteria, and approaches to pharmacological and surgical management. Case report. Case of young male (born in 1997) suffering from dysphagia with regular episodes of food impaction in the esophagus are described. Multiple endoscopic studies in the patient medical history did not reveal obvious causes for the episodes of acute obstructive dysphagia; however, in neither case were esophageal biopsies performed or adequate pharmacological therapy initiated. The outcome of a prolonged (7—10 years) active immune-inflammatory process in the esophagus was the development of severe fibrostenotic changes in the esophageal wall, such as rings and strictures with a diameter less than 5 mm. These complications led to severe dysphagia, weight loss, and a marked decrease in quality of life. Pharmacological therapy and balloon dilation of the esophageal strictures helped reduce symptom severity. However, the developed fibrostenotic complications resulted in irreversible remodeling of the esophageal wall in this young man. Conclusion. The presented case underscore the importance of timely disease diagnosis and the initiation of pharmacological therapy to prevent the progression of inflammatory processes and the development of irreversible fibrosclerotic changes in the esophageal wall. In cases where strictures and dysphagia have already developed and do not resolve with pharmacological therapy, patients with eosinophilic esophagitis require endoscopic intervention (balloon dilation or bougienage of the esophagus) to resolve dysphagia and normalize their quality of life.

  • Open Access

    Current Clinical Guidelines for the Management of Patients with Eosinophilic Esophagitis

    by Oksana M. Drapkina, Vladimir T. Ivashkin, Igor V. Maev, Leyla S. Namazova-Baranova, Aleksandr A. Baranov, Musa R. Khaitov, Lyudmila M. Mikhaleva, Valeria O. Kaybysheva, Elena A. Vishneva, Evgeniy D. Fedorov, et al.

    This article presents an analysis of current clinical guidelines for the management of patients with eosinophilic esophagitis (EoE) — a chronic immune-mediated disease of the esophagus characterized by eosinophilic infiltration of the mucosa (≥ 15 eos/hpf) and clinical manifestations of esophageal dysfunction. The review highlights key changes in diagnostic approaches and discusses contemporary treatment strategies, including dietary therapy (starting with the least restrictive diets), pharmacological treatment (proton pump inhibitors, topical steroids, biologic therapy), and endoscopic dilation for strictures. The authors emphasize the need for comprehensive monitoring (clinical, endoscopic, and histological) to assess treatment response and for long-term maintenance therapy given the chronic nature of the disease. Special attention is paid to pediatric aspects of patient management.


  • Clinical and morphological characteristics of eosinophilic esophagitis with surgical complications

    by V. O. Kaybysheva, E. V. Gorbachev, A. I. Mokritsky, E. D. Fedorov, S. G. Shapovalyants

    Objective. To study the clinical, laboratory, endoscopic, and pathomorphological features of eosinophilic esophagitis with surgical complications. Material and methods. 113 patients with a confirmed eosinophilic esophagitis (based on esophagogastroduodenoscopy with esophageal biopsy) underwent a comprehensive examination including assessment of complaints, medical history, comorbidities, and nutritional status. Laboratory blood tests, esophagogastroduodenoscopy with endocytoscopy and esophageal biopsy, and pathomorphological examination of biopsy specimens were performed. Some patients also underwent barium esophagogram. Results. Complications leading to endoscopic and/or surgical interventions were recorded in 27.4% of patients with eosinophilic esophagitis. Complicated forms of eosinophilic esophagitis were characterized by more severe clinical manifestations (dysphagia and food impaction were observed in 96.7% of patients), changes in laboratory tests (blood eosinophilia and elevated IgE level), a high score on the EREхFS scale (more than 6 points), detection of strictures during endoscopic examination, and fibrosis in the subepithelial layer upon histopathological examination. Conclusion. One-third of eosinophilic esophagitis cases are complicated, requiring patients to seek urgent endoscopic and surgical care. Most patients with a complicated course are young men under 30 years of age, suffering from persistent dysphagia and recurrent food impaction episodes. Esophagogastroduodenoscopy in patients with eosinophilic esophagitis reveals characteristic signs of mucosal inflammation – edema, exudate, and longitudinal furrows; in cases of delayed diagnosis, rings and strictures are found in the esophagus. To prevent complications, every patient with unexplained dysphagia (especially with episodes of food impaction) should undergo endoscopic examination of the esophagus with multiple biopsies for timely diagnosis and initiation of anti-inflammatory therapy.

  • Efficacy of Elimination Diets in the Treatment of Adult Patients with Eosinophilic Esophagitis

    by V. O. Kaybysheva, S. V. Tikhonov, E. D. Fedorov, S. G. Shapovalianc

    Aim : to assess the efficacy of dietary treatment regimens in eosinophilic esophagitis patients. Materials and methods. Twenty-seven patients (1 woman and 26 men) aged 24 to 61 years with a previously confirmed diagnosis of eosinophilic esophagitis (according to esophagogastroduodenoscopy with esophageal biopsy: > 15 eosinophils per high-power field, ×400) off therapy were instructed on dietary exclusions as the only treatment method. Three patients were placed on a targeted diet based on allergy testing; 17 patients followed a two-food elimination diet; and 7 patients followed a six-food elimination diet. All patients underwent esophagogastroduodenoscopy with esophageal biopsy (6 specimens from the distal and middle/proximal portions) and histopathological examination of biopsy specimens, as well as questionnaire-based assessment of dysphagia severity before and after 12 weeks of dietary therapy. Results . After 12 weeks of dietary therapy, histological remission was achieved in 3 of 7 (42.9 %) patients who followed the six-food elimination diet, in 7 of 17 (41.2 %) patients who followed two-food elimination diet, and in 1 of 3 (33.3 %) patients on a target diet (differences were not statistically significant). Complete resolution of dysphagia was ob served in 1 (33.3 %) patient who followed a target diet, in 8 of 14 (57.1 %) patients with dysphagia in the two-food elimination diet group, and in 3 of 5 (60 %) patients with dysphagia on the six-food elimination diet (differences were not statistically significant). Conclusions . The efficacy of two-food and six-food elimination diets is comparable and allows histological remis sion to be achieved in 41.2–42.9 % of patients with eosinophilic esophagitis.

  • Data of pH-impedance monitoring in eosinophilic esophagitis patients

    by V. O. Kaybysheva, A. I. Mokritsky, E. D. Fedorov, S. G. Shapovalyants

    One of the key factors in the pathogenesis of eosinophilic esophagitis is the disruption of the epithelial barrier integrity, leading to deep penetration of environmental allergens into the esophageal mucosa. The causes of dilated intercellular spaces in eosinophilic esophagitis are recognized as inflammatory processes induced by type T2cytokines (IL-4, 5, 13), as well as a genetically determined impairment in the synthesis of tight junction proteins. At the same time, the contribution of pathological gastroesophageal refluxes to mucosal damage and increased permeability of the esophagus cannot be ruled out. Given the high prevalence of gastroesophageal reflux disease in the population, this may play an important role in the pathogenetic processes occurring in the esophageal wall of patients with eosinophilic esophagitis. Aim. To study the parameters of 24-hour pH-impedance monitoring in patients with eosinophilic esophagitis in order to assess the role of gastroesophageal refluxes in the pathogenesis of eosinophilic esophagitis and to determine treatment strategies for patients with eosinophilic esophagitis. Material and methods. 24-hour esophageal pH-impedance monitoring was performed on 57 patients aged 18 to 52 years with a previously confirmed diagnosis of "eosinophilic esophagitis," who provided signed voluntary informed consent. The study results were evaluated in comparison with pH-impedance monitoring data from patients with gastroesophageal reflux disease (60 individuals) and healthy volunteers (23 individuals). Results. Pathological gastroesophageal refluxes (primarily acidic) likely play a significant role in the pathogenesis of eosinophilic esophagitis, as they were detected in this study in 21.1% of patients with eosinophilic esophagitis. Routine pH-impedance monitoring is not indicated for eosinophilic esophagitis but may be used as an additional diagnostic method in patients when determining therapeutic strategy (prescribing antisecretory therapy or topical corticosteroids). Assessment of basal nocturnal impedance may be an important additional marker of inflammatory process activity in patients with EoE.

  • Pathomorphological features of eosinophilic esophagitis before and after treatment with proton pomp inhibitors

    by E.N. Motylev, L.M. Mikhaleva, K.S. Maslenkina, A.I. Mikhalev, M.Y. Gushchin, E.O. Zentsova, A.E. Birukov, V.O. Kaybysheva

    Eosinophilic esophagitis (EoE) is characterized by predominant eosinophilic infiltration of esophageal mucosa, >15 eosinophils in a high power field (HPF). Proton pomp inhibitors (PPI) are medications of choice to start therapy of EoE. Objective. To perform histological and morphometric analysis of biopsy pieces of esophageal mucosa before and after treatment with PPI. Material and methods. Of the 84 patients newly diagnosed with EoE, 30 were in the PPI therapy group. Patients underwent esophagogastroduodenoscopy with biopsy for initial diagnosis and follow-up evaluation. Biopsy specimens were stained with hematoxylin and eosin, combined PAS/Alcian blue staining and Mallory staining to detect fibrosis. Morphometric analysis was performed using the Eosinophilic Esophagitis Histologic Scoring System (EoEHSS) for initial diagnosis and Eosinophilic Esophagitis Histology Remission Score (EoEHRS) to assess the onset of remission. Results. In initial biopsies peak eosinophil count comprised 46 (25—89) eosinophils HPF, rates of basal zone hyperplasia and dilated intercellular spaces were both 100%, followed by lamina propria fibrosis (98.04%), surface epithelial alteration (77.38%), eosinophilic abscesses (57.14%), eosinophil surface layering (28.57%) and dyskeratosis (21.43%). Using EoEHSS, the total score for the grade was 12 (8—13.75) and the total score for the stage was 10 (8—12). Peak eosinophil count after the treatment alleviated in all the patients (4 (1—12) eosinophils HPF, p<0.05). The severity and the extent of other parameters has significantly decreased. Using EoEHSS, the total score for the grade was 4 [3—8] and the total score for the stage was 4 (3—7), p<0.05. Conclusion. Not only peak eosinophil count, but structural changes of esophageal mucosa should be taken into account while evaluating biopsies for initial diagnostic and to analyze the treatment response. EoEHRS remission criteria were reached in 40% patients on PPI therapy.

  • Dietary therapy in eosinophilic esophagitis: a case series

    by V.O. Kaibysheva, E.D. Fedorov, S.G. Shapovalyants

    Objective. To synthesize current evidence on the efficacy of dietary interventions in patients with eosinophilic esophagitis and to illustrate the clinical application of dietary therapy using case series. Key points. Dietary therapy as a first-line treatment for eosinophilic esophagitis demonstrates efficacy comparable to pharmacologic therapy with proton pump inhibitors and topical corticosteroids. A six-food elimination diet achieves histological remission in 61.3—63.9% of patients. Less restrictive regimens excluding only milk and dairy products are associated with remission rates of approximately 46.4—51.4%. Elimination diets excluding two or four food groups result in histological remission in 44.3—54.7% of cases. Elemental diets based on amino acid formulas induce remission in more than 90% of patients; however, their clinical utility is limited by poor adherence and they should be reserved for cases refractory to other therapeutic approaches. Diets guided by allergy testing (skin prick tests and serum-specific IgE) show the lowest and most variable efficacy (39.5—45.7%), which restricts their role in the management of eosinophilic esophagitis. Conclusion. Elimination diets may be employed in eosinophilic esophagitis either as monotherapy or in combination with pharmacologic treatment when monotherapy is insufficient. Current dietary strategies favor initiating treatment with less restrictive regimens (exclusion of dairy products alone or milk and gluten), followed by a step-up approach with broader food elimination in patients who fail to achieve histological remission. Diets based on allergy testing are appropriate only in patients with confirmed concomitant food allergy.

  • The choice of the method of intraluminal endoscopic treatment of patients with achalasia of the cardia

    by R.V. Plakhov, E.D. Fedorov, S.G. Shapovaliants, S.A. Budzinskiy, E.V. Gorbachev, V.O. Kaybysheva, R.R. Denishev

    Background. Among all intraluminal endoscopic treatments for patients with achalasia cardia (AC), endoscopic balloon pneumacardiodilation (EBPD) and peroral endoscopic myotomy (POEM) are the most interesting. Objective. To study and compare immediate and long-term results of EBPD and POEM in patients with AC on the basis of prospective randomized study. Material and methods. The study included 25 patients with AC of the 1st or 2nd types according to Chicago classification, who had the 2nd or 3rd stage of the disease according to B.V. Petrovsky. After detailed examination all patients were divided into two groups by the stratification block randomization method: in group 1 EBPD was performed, in group 2 — POEM. Results. In group 1 11 EBPD were performed, in group 2 — 14 POEM. All interventions were performed without complications. The mean and absolute duration of EBPD, as well as the duration of hospitalization in group 1 (26.4±9.6 min; 50 min; 3.6±0.9 days) were statistically significantly shorter than in group 2 patients who underwent POEM (96.8±49.1 min; 180 min; 7.0±2.1 days) (p<0.01). All interventions resulted in the relief of dysphagia phenomena. According to the results of clinical and instrumental examination after 1 month, no statistical differences were found in patients of both groups. In 12 months after single EBPD recurrence of AC was registered in 45.4% of patients; after POEM no cases of disease recurrence were registered, and endoscopic signs of terminal esophagitis stage A were revealed in 8.3% of cases. Conclusion. EBPD has advantages over POEM according to the results of evaluation of immediate treatment results, similar clinical effect in the nearest period, but it is considerably inferior to POEM with respect to the reduction of clinical symptoms of AC: 12 months after a single EBPD 43.4% of cases of disease recurrence were registered, while no similar observations were made after POEM.

  • Open Access

    Eosinophilic esophagitis. A new T2-type immune-mediated inflammatory disease of the esophagus

    by V. O. Kaibysheva, E. D. Fedorov, S. G. Shapovalyants

    Objective. To present current perspectives on the epidemiology, etiology, and pathogenesis of eosinophilic esophagitis (EoE). Main Points. Eosinophilic esophagitis is a chronic, inflammatory, immune-mediated disease of the esophagus. Its pathogenesis is based on a predisposition to mount an immune response via the activation of type 2 T-helper (Th2) cells, which, upon contact with exogenous allergens, express a highly active group of cytokines. The high concentration of Th2 cytokines in the esophageal mucosa leads to eosinophilic infiltration throughout the entire length of the esophageal wall (from the proximal to the distal segments), the development of chronic inflammation within the epithelium and the lamina propria, and the development of subepithelial fibrosis. Patients with EoE often have concomitant Th2-associated inflammatory diseases (such as bronchial asthma, rhinitis, conjunctivitis, hay fever, etc.). Timely diagnosis and adequate treatment of eosinophilic esophagitis can prevent the development of strictures and other complications of the disease.